OncoMatch/Clinical Trials/NCT06153251
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Is NCT06153251 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including BMS-986453 and Fludarabine for relapsed and/or refractory multiple myeloma.
Treatment: BMS-986453 · Fludarabine · Cyclophosphamide — The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: proteasome inhibitor
Must have received: immunomodulatory agent
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham · Birmingham, Alabama
- City of Hope Comprehensive Cancer Center · Duarte, California
- UCSF Helen Diller Medical Center at Parnassus Heights · San Francisco, California
- Stanford University Medical Center · Stanford, California
- Colorado Blood Cancer Institute · Denver, Colorado
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06153251 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received proteasome inhibitor and immunomodulatory agent.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages